538 related articles for article (PubMed ID: 25464111)
1. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions.
Song H; Zhu J; Lu D
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010623. PubMed ID: 25464111
[TBL] [Abstract][Full Text] [Related]
2. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions?
Eslami L; Nasseri-Moghaddam S
Arch Iran Med; 2013 Aug; 16(8):449-58. PubMed ID: 23906249
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Deprescribing versus continuation of chronic proton pump inhibitor use in adults.
Boghossian TA; Rashid FJ; Thompson W; Welch V; Moayyedi P; Rojas-Fernandez C; Pottie K; Farrell B
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011969. PubMed ID: 28301676
[TBL] [Abstract][Full Text] [Related]
5. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.
Lundell L; Vieth M; Gibson F; Nagy P; Kahrilas PJ
Aliment Pharmacol Ther; 2015 Sep; 42(6):649-63. PubMed ID: 26177572
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological treatment of children with gastro-oesophageal reflux.
Tighe M; Afzal NA; Bevan A; Hayen A; Munro A; Beattie RM
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD008550. PubMed ID: 25419906
[TBL] [Abstract][Full Text] [Related]
7. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis.
Trinh VQ; Shi C; Ma C
Histopathology; 2020 Dec; 77(6):865-876. PubMed ID: 32702178
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors for functional dyspepsia.
Pinto-Sanchez MI; Yuan Y; Hassan A; Bercik P; Moayyedi P
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011194. PubMed ID: 29161458
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Proton Pump Inhibitors on the Development of Gastric Neoplastic Lesions in Patients With Autoimmune Atrophic Gastritis.
Dilaghi E; Bellisario M; Esposito G; Carabotti M; Annibale B; Lahner E
Front Immunol; 2022; 13():910077. PubMed ID: 35935934
[TBL] [Abstract][Full Text] [Related]
10. Molecular-targeted first-line therapy for advanced gastric cancer.
Song H; Zhu J; Lu D
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011461. PubMed ID: 27432490
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors for functional dyspepsia.
Pinto-Sanchez MI; Yuan Y; Bercik P; Moayyedi P
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011194. PubMed ID: 28271513
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors for chronic obstructive pulmonary disease.
Kikuchi S; Imai H; Tani Y; Tajiri T; Watanabe N
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013113. PubMed ID: 32844430
[TBL] [Abstract][Full Text] [Related]
13. Gastric carcinoids after long-term use of a proton pump inhibitor.
Jianu CS; Fossmark R; Viset T; Qvigstad G; Sørdal O; Mårvik R; Waldum HL
Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200
[TBL] [Abstract][Full Text] [Related]
14. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
van Pinxteren B; Numans ME; Bonis PA; Lau J
Cochrane Database Syst Rev; 2006 Jul; (3):CD002095. PubMed ID: 16855986
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding.
Kanno T; Yuan Y; Tse F; Howden CW; Moayyedi P; Leontiadis GI
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD005415. PubMed ID: 34995368
[TBL] [Abstract][Full Text] [Related]
16. WITHDRAWN: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease.
Donnellan C; Preston C; Moayyedi P; Sharma N
Cochrane Database Syst Rev; 2010 Feb; (2):CD003245. PubMed ID: 20166065
[TBL] [Abstract][Full Text] [Related]
17. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease.
Donnellan C; Sharma N; Preston C; Moayyedi P
Cochrane Database Syst Rev; 2005 Apr; (2):CD003245. PubMed ID: 15846653
[TBL] [Abstract][Full Text] [Related]
18. Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis.
Zheng Z; Lu Z; Song Y
Front Pharmacol; 2023; 14():1244400. PubMed ID: 37693896
[No Abstract] [Full Text] [Related]
19. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
van Pinxteren B; Sigterman KE; Bonis P; Lau J; Numans ME
Cochrane Database Syst Rev; 2010 Nov; (11):CD002095. PubMed ID: 21069670
[TBL] [Abstract][Full Text] [Related]
20. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
Sigterman KE; van Pinxteren B; Bonis PA; Lau J; Numans ME
Cochrane Database Syst Rev; 2013 May; 2013(5):CD002095. PubMed ID: 23728637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
